Recent News

• 04.22.2025 - TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
• 04.16.2025 - TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025
• 03.17.2025 - TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
• 03.05.2025 - TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
• 02.25.2025 - TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
• 01.29.2025 - TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
• 01.15.2025 - TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
• 12.19.2024 - TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
• 12.09.2024 - TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

Recent Filings

• 04.21.2025 - DEF 14A Other definitive proxy statements
• 04.21.2025 - ARS Annual Report to Security Holders
• 04.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.11.2025 - PRE 14A Other preliminary proxy statements
• 04.11.2025 - 8-K Current report
• 04.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
• 03.21.2025 - 8-K Current report